TDMS Study 96007-04 Pathology Tables
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 09/29/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Time: 12:14:44
FINAL#4/RATS
Facility: Battelle Columbus Laboratory
Chemical CAS #: TEFDIOXINMIX
Lock Date: 09/12/01
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 1
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 09/29/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Time: 12:14:44
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 98 98 98 98
Early Deaths
Moribund Sacrifice 26 25 22 25 33
Natural Death 11 5 6 4 10
Dosing Accident 1 1 2
Survivors
Terminal Sacrifice 16 23 24 23 8
Animals Examined Microscopically 53 53 53 53 53
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (53) (53) (53) (53) (53)
Muscularis, Inflammation 2 [1.0] 1 [2.0] 1 [1.0]
Intestine Large, Colon (53) (52) (53) (53) (51)
Parasite Metazoan 1
Intestine Large, Rectum (52) (53) (53) (53) (52)
Parasite Metazoan 2 4 5 1
Artery, Inflammation, Chronic Active 2 [2.5] 3 [3.0]
Serosa, Inflammation 1 [3.0]
Intestine Large, Cecum (51) (53) (53) (53) (51)
Artery, Inflammation, Chronic Active 1 [2.0]
Intestine Small, Duodenum (52) (53) (53) (53) (52)
Serosa, Inflammation, Chronic Active 1 [3.0]
Liver (53) (53) (53) (53) (51)
Angiectasis 3 [1.7] 2 [1.5] 3 [1.0]
Basophilic Focus 9 14 10 5 8
Basophilic Focus, Multiple 15 12 3 7 8
Cholangiofibrosis 2 [1.0] 3 [2.0] 4 [2.5] 17 [2.3]
Clear Cell Focus 1 1
Clear Cell Focus, Multiple 1 1
Degeneration, Cystic 1 [1.0] 1 [1.0] 2 [1.0]
Eosinophilic Focus 4 2 5 5
Eosinophilic Focus, Multiple 1 7 6 15 19
Fatty Change, Diffuse 3 [2.3] 5 [1.0] 14 [1.0] 34 [1.1] 36 [1.3]
Fatty Change, Focal 3 [1.3] 4 [1.5] 7 [1.6] 2 [1.5] 1 [1.0]
Hematopoietic Cell Proliferation 16 [1.1] 18 [1.1] 19 [1.1] 8 [1.0] 9 [1.1]
Hepatodiaphragmatic Nodule 1
Hyperplasia, Nodular 1 3 11 38
Inflammation 36 [1.1] 50 [1.1] 45 [1.2] 50 [1.3] 50 [1.3]
Karyomegaly 1 [3.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 2
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 09/29/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Time: 12:14:44
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Mixed Cell Focus 4 5 5 1
Mixed Cell Focus, Multiple 17 27 30 35 17
Necrosis 3 [1.7] 1 [2.0] 9 [2.2] 3 [1.7] 15 [2.2]
Pigmentation 4 [1.5] 35 [1.3] 41 [1.2] 48 [1.9] 51 [2.2]
Toxic Hepatopathy 5 [1.0] 14 [1.0] 38 [1.6] 47 [3.1]
Bile Duct, Cyst 1 [3.0] 3 [2.7] 3 [2.3] 4 [2.3] 9 [2.0]
Bile Duct, Dilatation 1 [1.0] 1 [3.0]
Bile Duct, Fibrosis 3 [1.7] 2 [1.0] 1 [1.0] 5 [1.4] 1 [2.0]
Bile Duct, Hyperplasia 2 [1.5] 3 [1.3] 5 [1.4] 25 [1.4] 42 [1.9]
Centrilobular, Degeneration 3 [1.7] 2 [2.0] 1 [3.0] 1 [2.0] 6 [2.2]
Centrilobular, Fibrosis 1 [1.0]
Hepatocyte, Hypertrophy 1 [1.0] 27 [1.1] 34 [1.2] 46 [1.5] 50 [3.0]
Hepatocyte, Multinucleated 12 [1.0] 10 [1.2] 39 [1.5] 51 [2.1]
Oval Cell, Hyperplasia 1 [1.0] 1 [1.0] 26 [1.4] 42 [2.2]
Portal, Fibrosis 11 [1.9]
Serosa, Fibrosis 1 [2.0]
Serosa, Inflammation, Chronic 1 [2.0]
Mesentery (1) (2) (6) (8)
Inflammation, Chronic Active 2 [3.0]
Necrosis 1 [3.0] 1 [4.0]
Artery, Inflammation, Chronic Active 1 [4.0] 3 [3.7] 6 [3.7]
Fat, Necrosis 1 [3.0] 2 [3.0]
Oral Mucosa (10) (18) (19) (29) (31)
Gingival, Hyperplasia, Squamous 8 [1.5] 17 [1.5] 18 [1.4] 26 [1.6] 30 [1.6]
Pancreas (52) (53) (53) (53) (51)
Degeneration 1 [2.0]
Inflammation, Chronic Active 3 [1.7] 1 [3.0] 6 [1.3] 7 [1.7] 16 [1.8]
Inflammation, Granulomatous 1 [2.0]
Acinus, Atrophy 3 [1.3] 2 [1.0] 7 [1.7] 7 [1.7] 20 [2.0]
Acinus, Hyperplasia 2 [1.5] 1 [2.0]
Acinus, Vacuolization Cytoplasmic 1 [1.0] 3 [1.3] 15 [1.0] 30 [1.1]
Artery, Inflammation, Chronic Active 6 [2.2] 3 [1.7] 8 [2.6] 14 [2.9]
Duct, Cyst 1 [2.0]
Duct, Dilatation 5 [3.0]
Duct, Inflammation, Chronic Active 2 [3.5]
Salivary Glands (53) (53) (53) (53) (53)
Atrophy 1 [3.0]
Inflammation 2 [2.0] 1 [3.0]
Mineralization 1 [2.0]
Stomach, Forestomach (53) (53) (53) (53) (52)
Cyst 1 [3.0] 1 [3.0]
Diverticulum 1
Edema 1 [3.0] 1 [3.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 3
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 09/29/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Time: 12:14:44
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Erosion 1 [1.0]
Hyperkeratosis 2 [2.5] 2 [2.0]
Hyperplasia, Squamous 5 [2.4] 1 [2.0] 4 [2.3] 9 [1.7] 6 [2.5]
Inflammation 2 [2.5] 2 [2.5] 1 [3.0] 3 [1.7]
Mineralization 1 [2.0] 4 [1.5] 2 [1.0]
Ulcer 3 [3.0] 2 [2.5] 1 [2.0] 2 [2.0]
Artery, Inflammation, Chronic Active 2 [2.5] 1 [3.0]
Stomach, Glandular (53) (53) (53) (53) (52)
Erosion 1 [2.0]
Mineralization 2 [2.0] 4 [1.5] 3 [1.3] 3 [1.7] 1 [2.0]
Artery, Inflammation, Chronic Active 2 [3.0]
Tongue (1) (1)
Infiltration Cellular 1 [3.0]
Tooth (24) (23) (27) (37) (30)
Peridontal Tissue, Inflammation 23 [1.1] 21 [1.3] 22 [1.2] 34 [1.3] 30 [1.7]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (53) (53) (53) (52) (53)
Aorta, Mineralization 1 [2.0] 3 [2.3]
Heart (53) (53) (53) (52) (53)
Cardiomyopathy 11 [1.0] 26 [1.0] 31 [1.1] 30 [1.1] 32 [1.1]
Inflammation, Suppurative 1 [3.0] 1 [4.0]
Mineralization 1 [2.0]
Necrosis 1 [3.0]
Thrombosis 1 [3.0] 1 [3.0]
Artery, Degeneration 1 [2.0] 1 [2.0]
Artery, Inflammation, Chronic Active 1 [2.0] 1 [2.0]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (52) (53) (53) (53) (51)
Angiectasis 15 [1.7] 20 [1.6] 18 [1.5] 17 [1.6] 8 [1.6]
Atrophy 3 [2.3] 18 [2.7]
Degeneration, Cystic 9 [2.4] 15 [2.3] 19 [2.3] 25 [2.3] 16 [2.1]
Hematopoietic Cell Proliferation 1 [1.0] 1 [1.0]
Hyperplasia 12 [2.5] 26 [2.4] 23 [2.8] 25 [2.6] 21 [2.5]
Hypertrophy 44 [2.1] 45 [2.2] 47 [2.4] 46 [2.5] 45 [2.3]
Inflammation 1 [2.0]
Mineralization 1 [3.0] 1 [3.0]
Necrosis 2 [3.0] 2 [2.5] 2 [2.5]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 4
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 09/29/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Time: 12:14:44
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Thrombosis 1 [3.0]
Vacuolization Cytoplasmic 6 [1.2] 13 [1.5] 11 [1.5] 7 [1.7] 15 [1.5]
Capsule, Inflammation 1 [2.0] 1 [3.0]
Adrenal Medulla (52) (53) (53) (53) (51)
Hyperplasia 10 [2.2] 21 [2.0] 12 [1.8] 15 [1.7] 9 [1.6]
Islets, Pancreatic (52) (53) (53) (53) (51)
Hyperplasia 1 [2.0] 2 [2.0]
Pituitary Gland (53) (53) (53) (53) (53)
Angiectasis 6 [1.7] 1 [1.0] 2 [2.5] 3 [2.3]
Cyst 1 [2.0] 1 [2.0] 2 [1.5]
Cytoplasmic Alteration 3 [1.3]
Hemorrhage 1 [2.0]
Vacuolization Cytoplasmic 1 [1.0] 2 [1.0] 3 [1.3] 1 [1.0]
Pars Distalis, Hyperplasia 18 [2.5] 19 [2.3] 24 [2.5] 20 [2.5] 19 [2.1]
Pars Intermedia, Cyst 1 [3.0]
Thyroid Gland (53) (53) (51) (52) (51)
C-Cell, Hyperplasia 24 [2.3] 24 [2.3] 20 [2.1] 18 [2.3] 14 [2.0]
Follicular Cell, Hyperplasia 1 [1.0]
Follicular Cell, Hypertrophy 4 [1.5] 13 [1.1] 12 [1.5] 18 [1.7] 23 [1.9]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (51) (53) (53) (51) (50)
Hyperplasia, Squamous 1 [2.0]
Inflammation 42 [1.7] 40 [1.7] 37 [1.3] 33 [1.3] 29 [1.1]
Duct, Cyst 39 [2.3] 41 [2.5] 44 [2.1] 39 [2.3] 44 [2.3]
Ovary (52) (52) (53) (53) (51)
Atrophy 44 [4.0] 44 [4.0] 43 [4.0] 49 [3.9] 40 [4.0]
Cyst 8 [2.6] 16 [2.4] 20 [2.3] 14 [2.3] 7 [2.3]
Fibrosis 1 [3.0]
Hemorrhage 1 [2.0]
Inflammation, Chronic Active 2 [3.0] 1 [4.0] 2 [3.5] 5 [3.6]
Artery, Inflammation, Chronic Active 1 [4.0]
Oviduct (2) (2) (5)
Cyst 2 [2.0] 1 [2.0]
Inflammation, Chronic Active 2 [4.0] 4 [4.0]
Uterus (52) (53) (53) (53) (51)
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 5
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 09/29/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Time: 12:14:44
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Adenomyosis 1 [2.0] 1 [2.0] 2 [2.0] 1 [2.0]
Hemorrhage 1 [3.0] 1 [2.0]
Inflammation, Chronic Active 1 [2.0] 1 [3.0] 1 [3.0] 1 [4.0] 3 [3.0]
Inflammation, Suppurative 6 [1.8] 5 [2.2] 9 [1.8] 13 [1.8] 6 [3.2]
Metaplasia, Squamous 21 [2.0] 32 [2.2] 32 [2.3] 35 [2.4] 30 [2.4]
Necrosis 1 [4.0]
Thrombosis 1 [3.0]
Ulcer 1 [2.0] 1 [3.0]
Cervix, Hyperplasia, Stromal 1 [4.0]
Endometrium, Fibrosis 1 [2.0]
Endometrium, Hyperplasia, Cystic 37 [1.9] 35 [2.2] 34 [2.1] 33 [2.2] 23 [2.1]
Epithelium, Necrosis 1 [4.0]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (53) (53) (53) (53)
Hyperplasia 36 [3.1] 36 [2.8] 34 [2.7] 41 [3.0] 48 [3.0]
Lymph Node (4) (1) (2) (9) (11)
Lumbar, Ectasia 1 [2.0]
Lumbar, Hemorrhage 1 [2.0]
Lumbar, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0]
Lumbar, Hyperplasia, Plasma Cell 1 [2.0] 3 [2.3]
Mediastinal, Ectasia 1 [2.0] 4 [2.0] 2 [2.0]
Mediastinal, Fibrosis 1 [2.0]
Mediastinal, Hemorrhage 1 [2.0] 2 [2.0]
Mediastinal, Hyperplasia, Histiocytic 1 [2.0] 1 [2.0]
Mediastinal, Hyperplasia, Lymphoid 2 [2.5]
Mediastinal, Hyperplasia, Plasma Cell 3 [2.3]
Pancreatic, Ectasia 1 [3.0]
Pancreatic, Hyperplasia 1 [4.0]
Pancreatic, Hyperplasia, Histiocytic 1 [2.0]
Popliteal, Hyperplasia, Plasma Cell 1 [3.0]
Renal, Hyperplasia, Histiocytic 1 [3.0]
Lymph Node, Mandibular (53) (53) (53) (53) (53)
Ectasia 1 [2.0] 1 [2.0] 2 [3.0]
Hemorrhage 1 [1.0]
Hyperplasia, Plasma Cell 31 [2.1] 42 [2.1] 30 [2.1] 22 [2.3] 27 [2.3]
Necrosis, Focal 1 [3.0]
Lymph Node, Mesenteric (52) (53) (53) (53) (50)
Ectasia 1 [2.0]
Hemorrhage 1 [3.0] 1 [2.0]
Hyperplasia 1 [4.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 6
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 09/29/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Time: 12:14:44
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Hyperplasia, Histiocytic 1 [2.0] 1 [2.0]
Hyperplasia, Lymphoid 1 [4.0]
Pigmentation 1 [3.0]
Spleen (52) (53) (53) (53) (51)
Hematopoietic Cell Proliferation 43 [1.8] 48 [1.5] 42 [1.5] 44 [1.6] 42 [1.6]
Hemorrhage 1 [2.0]
Inflammation, Suppurative 1 [2.0]
Necrosis 1 [3.0] 1 [3.0]
Pigmentation 45 [1.4] 50 [1.3] 52 [1.4] 47 [1.4] 46 [1.1]
Lymphoid Follicle, Atrophy 1 [2.0] 2 [3.0] 3 [2.0] 2 [2.5] 3 [2.3]
Red Pulp, Atrophy 1 [2.0] 3 [2.0]
Thymus (52) (48) (50) (53) (50)
Atrophy 32 [2.3] 43 [2.9] 45 [3.3] 50 [3.7] 48 [3.9]
Cyst 2 [2.5]
Ectopic Thyroid 1 [4.0]
Hemorrhage 1 [3.0]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (53) (53) (53) (53) (52)
Cyst 3 [2.7] 1 [2.0] 1 [3.0]
Hyperplasia 22 [1.2] 7 [1.6] 14 [1.1] 12 [1.0] 9 [1.0]
Inflammation, Granulomatous 3 [1.3] 4 [1.8] 1 [3.0] 3 [3.0] 1 [2.0]
Inflammation, Suppurative 1 [2.0]
Skin (53) (53) (53) (53) (53)
Cyst Epithelial Inclusion 2 1 3 3
Hyperkeratosis 1 [2.0]
Inflammation, Suppurative 1 [2.0]
Ulcer 1 [3.0] 1 [2.0]
Hair Follicle, Atrophy 1 [4.0]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (53) (53) (53) (53) (53)
Mineralization 1 [1.0]
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (53) (53) (53) (53)
Edema 1 [1.0] 3 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 7
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 09/29/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Time: 12:14:44
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM - CONT
Gliosis 1 [3.0] 1 [3.0]
Hemorrhage 1 [2.0]
Hydrocephalus 1 [1.0] 4 [1.3] 2 [2.0] 2 [2.0]
Inflammation, Granulomatous 1 [2.0]
Mineralization 1 [2.0] 1 [1.0] 1 [1.0]
Necrosis 3 [1.7]
Artery, Degeneration 1 [3.0]
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (53) (53) (53) (53) (53)
Congestion 1 [3.0] 1 [3.0]
Cyst 1 [3.0]
Edema 2 [2.0] 2 [2.5] 1 [2.0]
Hemorrhage 1 [2.0] 1 [1.0]
Infiltration Cellular, Histiocyte 43 [1.9] 50 [1.9] 48 [1.6] 48 [1.6] 50 [1.4]
Inflammation 4 [1.5] 2 [2.0] 3 [2.0] 1 [3.0] 2 [3.0]
Metaplasia, Squamous 2 [2.0] 2 [2.0] 8 [2.0] 11 [1.9]
Mineralization 1 [1.0]
Alveolar Epithelium, Hyperplasia 21 [1.3] 25 [1.0] 10 [1.3] 2 [1.0] 2 [1.5]
Alveolar Epithelium, Metaplasia, Bronchiolar 20 [1.8] 33 [1.6] 41 [1.8] 40 [1.9]
Perivascular, Inflammation, Chronic Active 1 [3.0]
Nose (53) (53) (53) (53) (53)
Inflammation 1 [1.0] 2 [1.0] 2 [2.0] 1 [1.0] 1 [2.0]
Goblet Cell, Hyperplasia 2 [2.0] 1 [2.0]
Goblet Cell, Septum, Hyperplasia 1 [2.0]
Nasolacrimal Duct, Inflammation 1 [3.0]
Respiratory Epithelium, Hyperplasia 1 [1.0] 4 [1.8]
Turbinate, Cyst 1 [2.0]
Turbinate, Respiratory Epithelium,
Hyperplasia 1 [2.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (53) (53) (53) (53) (53)
Anterior Chamber, Ciliary Body, Iris,
Inflammation, Suppurative 1 [2.0]
Cornea, Inflammation, Suppurative 1 [3.0]
Lens, Degeneration 1 [4.0]
Retina, Atrophy 1 [3.0] 1 [4.0] 2 [2.0] 1 [2.0] 3 [2.0]
Harderian Gland (53) (53) (52) (53) (53)
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 8
NTP Experiment-Test: 96007-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 09/29/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (DIOXIN MIXTURE) Time: 12:14:44
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE TERT.MIX TERT.MIX TERT.MIX TERT.MIX TERT.MIX
CONTROL TEQ=10 TEQ=22 TEQ=46 TEQ=100
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM - CONT
Inflammation 8 [1.1] 11 [1.0] 4 [1.3] 5 [1.0] 7 [1.1]
Inflammation, Chronic Active 1 [4.0]
Necrosis 1 [4.0]
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (52) (53) (53) (53) (51)
Calculus Micro Observation Only 9 [1.6] 5 [1.8] 8 [1.6] 4 [2.0] 1 [2.0]
Casts Protein 1 [1.0] 1 [1.0]
Cyst 1 [2.0] 1 [3.0]
Developmental Malformation 1
Fibrosis 1 [2.0]
Inflammation, Chronic 1 [4.0]
Inflammation, Chronic Active 1 [2.0] 1 [4.0] 1 [3.0]
Inflammation, Suppurative 3 [1.3] 2 [1.0] 3 [1.0] 3 [1.7] 6 [2.8]
Mineralization 41 [1.0] 48 [1.0] 47 [1.1] 42 [1.1] 35 [1.2]
Nephropathy 26 [1.1] 41 [1.2] 40 [1.3] 47 [1.3] 49 [2.1]
Pelvis, Dilatation 2 [2.0] 1 [3.0] 1 [3.0] 1 [2.0]
Pelvis, Inflammation 2 [2.0] 1 [1.0] 1 [3.0] 2 [2.5] 1 [2.0]
Renal Tubule, Hyperplasia 2 [1.5]
Renal Tubule, Necrosis 1 [2.0] 1 [2.0]
Transitional Epithelium, Hyperplasia 5 [2.0] 5 [1.8] 8 [1.9] 10 [2.0] 8 [2.5]
Ureter (1) (1) (1) (1)
Cyst 1 [3.0]
Inflammation 1 [2.0]
Metaplasia, Squamous 1 [2.0]
Transitional Epithelium, Hyperplasia 1 [3.0] 1 [3.0]
Urinary Bladder (52) (52) (53) (53) (50)
Edema 1 [2.0]
Hemorrhage 1 [2.0]
Inflammation 12 [1.0] 3 [1.0] 4 [1.5] 8 [1.4] 5 [2.0]
Metaplasia, Squamous 1 [3.0]
Transitional Epithelium, Hyperplasia 1 [2.0] 3 [2.7] 4 [1.8]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 9
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------